Waisman Biomanufacturing

About Us

In the News

Press Releases & Publications

2024

February 6, 2024

Waisman Biomanufacturing and RoosterBio Announce Collaboration for GMP Manufacturing of Cell and Exosome Therapies

2023

November 20, 2023

Overcoming Bioprocessing Bottlenecks By Combining Adherent And Suspension Systems (cellandgene.com)

July 26, 2023

Bridging the Gap: How WB is Helping to Translate Research from Bench to Bedside

2022

July 5, 2022

BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

March 3, 2022

A science trailblazer retires: Stem cell researcher James Thomson's legacy changed the future of biology

February 22, 2022

Allogenic Cell Therapeutics: Successfully Creating Master Cell Banks, Working Cell Banks, and Drug Product

2021

June 15, 2021

FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns

2020

December 18, 2020

The Pace of a Pandemic Meets the Speed of Science As Wisconsin Takes On COVID-19

October 28, 2020

A major step for the polyvalent HIV vaccine – WHV manufactures world’s first four-valent gp120 protein vaccine

September 14, 2020

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

September 9, 2020

Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug

September 2, 2020

UW partners with biotech company to develop COVID-19 vaccine

August 3, 2020

UW connected company to manufacture COVID-19 vaccine

UW-Madison company to manufacture COVID-19 vaccine

Madison company to manufacture COVID-19 vaccine

UW lab partners with North Carolina company on COVID-19 vaccine

July 30, 2020

Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive Results

May 27, 2020

Heat Biologics Announces Collaboration with Waisman Biomanufacturing to Manufacture COVID-19 Vaccine

March 17, 2020

Stem Cell Therapy Trial Offers Hope To Osteoarthritis Patients

March 16, 2020

WHV completes manufacturing of DNA vaccine components

January 15, 2020

Glycan profiles of gp120 protein vaccines from four major HIV-1 subtypes 2 produced from different host cell lines under non-GMP or GMP conditions

2019

December 13, 2019

CLINICAL TRIAL FOR EBOLA VACCINE DEVELOPED AT UW–MADISON UNDERWAY IN JAPAN

August 12, 2019

Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110

2018

November 18, 2018

Artery banks may transform how we fight heart disease

November 4, 2018

Stem cell therapy developed at UW-Madison tested in clinical trial

October 4, 2018

Department of Defense grant for clinical trial of stem cell therapy for eye injuries

May 11, 2018

UW-Madison biomanufacturer offers essential gene-transfer capacity

March 26, 2018

UMass Medical School HIV vaccine to be tested in new Phase I trial

February 27, 2018

UW-Madison lab to make Ebola vaccine

February 27, 2018

Excellent Cohort A Data from Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial

February 21, 2018

Ebola vaccine inches toward human clinical trials

2017

September 27, 2017

Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology

September 12, 2017

UW–Madison to partner in $20 million cell-based therapy center

August 2, 2017

Madison Vaccines Announces First Patient Dosed in an Expanded Combination Trial of MVI-816 Plus KeyTruda® for Matastatic, Treatement-Resistant Prostate Cancer

July 5, 2017

Cynata Therapeutics : 17.07.05.FDA Meeting Provides Clear Path for US Development Plans

May 16. 2017

Patient Treatment Commences in Cynata’s World First Clinical Trial

2016

November 16, 2016

Morgridge–UW project investigates tissue-engineered arteries for transplant

November 9, 2016

Can artery ‘banks’ transform vascular medicine?

September 20, 2016

Cynata Approved to Launch World’s 1st Clinical Trial with an Allogeneic iPSC-Derived Product

August 1, 2016

Cynata Files Application to Commence Phase 1 Clinical Trial for CYP-001, World's First Allogeneic iPSC Product

June 22, 2016

UMMS receives $17.3 million to oversee manufacturing of HIV vaccine

April 7, 2016
Cynata Reports Compelling Results from Pre-clinical Stem Cell Study in Graft-versus-Host Disease (GvHD)

February 18, 2016

Agilis Biotherapeutics and Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement for Friedreich’s Ataxia Product

January 28, 2016
Cynata Receives Favourable Advice from UK Regulatory Authority – Prepares to Initiate Clinical Trial of 1st Allogenic iPSC-derived MSC Product

2015

September 15, 2015
Madison Vaccines Says Clinical Trial Begins for Its 2nd Prostate Cancer Vaccine, MVI-118, Intended to Delay Disease Progression in Men with Metastatic Disease

February 19, 2015
Cynata Achieves Major Stem Cell Manufacturing Milestone

February 12, 2015
Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)

2014

July 21, 2014


May 29, 2014

April 2014 - CTS Publication, Volume 7, Issue 2

An Update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy

April 11, 2014

February 16, 2014
Induced pluripotent stem cells as custom therapeutics for retinal repair: Progress and rationale

February 10, 2014
Cynata Partners With Leading Biologic Product Manufacturer

January 14, 2014
Spinoff joins fight against prostate cancer

January 14, 2014
Aduro Announces Phase 2 Clinical Trial Results Demonstrating Statistically Significant Survival Benefit in Pancreatic Cancer Patients Treated with its Novel Immunotherapies

2013

December 13, 2013
A new approach using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

October 2013 - ISCT Newsletter, Volume 20, No. 5
PACT Update: Cell Therapy for Regeneration of the Vocal Fold

October 17, 2013
Biomanufacturing center takes central role in developing stem-cell therapies

October 3, 2013
Banking Human Induced Pluripotent Stem Cells: Lessons Learned from Embryonic Stem Cells?

April 12, 2013
UW Stem Cell Researchers Building a 'Retinal Patch' to Restore Vision

February 10, 2013
Tom Still: Waisman Center's Four Decades of Research Changes Lives

2012

April 3, 2012
Madison researchers making major breakthroughs in stem cell work

March 11, 2012

Inviragen Hand, Foot and Mouth Disease Vaccine Generates Immune Response in 100% of Study Participants

January 21, 2012
Biomanufacturing Facility Adopts New Approach to Sterile Cleanroom Gowning

2010

November 17, 2010
Madison biotech company Stratatech awarded $3.5 million grant for cell therapy project being done in partnership with Waisman Biomanufacturing

May 14, 2010
The Problems and Promises of Stem Cell Research

March 3, 2010
NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)

February 17, 2010
Law, Ethics, Religion, and Clinical Translation in the 21st Century—A Discussion with Derek Hei

January 26, 2010
Federal grant funds productions of stem cells for clinical trials

November/December 2009 - ICTRToday Newsletter, Volume 2, No. 6
Waisman Biomanufacturing Facility Speeds Clinical Translation

2009 and earlier

September 17, 2009
(Stem cell) banking crisis

May 29, 2009
Waisman Clinical Biomanufacturing Facility and Nature Technology Team up on DNA Therapeutics Manufacturing

March 10, 2009
UW-Madison stem cell experts visit White House

December 15, 2005
Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates

August 29, 2005
UW's Waisman Center seeing strong demand for biomanufacturing facility time

May 9, 2000
Facility to bridge gap between discovery, therapy